Throughout its 40-year history, the field of gene therapy has been marked by many
transitions. It has seen great strides in combating human disease, has given hope to patients …

Over the last two decades, gene therapy vectors based on wild‐type Adeno‐associated
viruses (AAV) are safe and efficacious in numerous clinical trials and are translated into …

In the past two decades, adeno-associated virus (AAV) vector manufacturing has made
remarkable advancements to meet large-scale production demands for preclinical and …

Different approaches are used in the production of recombinant adeno-associated virus
(rAAV). The two leading approaches are transiently transfected human HEK293 cells and …

The gene therapy field has been galvanized by two technologies that have revolutionized
treating genetic diseases: vectors based on adeno-associated viruses (AAVs), and clustered …

Recombinant AAV (rAAV) is the most used delivery vector for clinical gene therapy.
However, many issues must be addressed before safer and more widespread …

We use cryoelectron microscopy (cryo-EM) as a sequence-and culture-independent
diagnostic tool to identify the etiological agent of an agricultural pandemic. For the past 4 …

Next-generation sequencing of single-stranded DNA (ssDNA) enables transgene
characterization of gene therapy vectors such as adeno-associated virus (AAV), but current …

Recombinant adeno-associated virus (rAAV) is an increasingly important gene therapy
vector, but its properties present unique challenges to critical quality attribute (CQA) …

Recombinant adeno-associated virus (rAAV) vectors are increasingly popular gene delivery
tools in biological systems. They are safe and lead to high-level, long-term transgene …